SG11201408168UA - Azetidine and piperidine compounds useful as pde10 inhibitors - Google Patents

Azetidine and piperidine compounds useful as pde10 inhibitors

Info

Publication number
SG11201408168UA
SG11201408168UA SG11201408168UA SG11201408168UA SG11201408168UA SG 11201408168U A SG11201408168U A SG 11201408168UA SG 11201408168U A SG11201408168U A SG 11201408168UA SG 11201408168U A SG11201408168U A SG 11201408168UA SG 11201408168U A SG11201408168U A SG 11201408168UA
Authority
SG
Singapore
Prior art keywords
california
international
amgen
azetidine
thousand oaks
Prior art date
Application number
SG11201408168UA
Inventor
Jennifer R Allen
Jian J Chen
Michael J Frohn
Matthew Richard Kaller
Qingyian Liu
Thomas T Nguyen
Alexander J Pickrell
Wenyuan Qian
Robert M Rzasa
Wenge Zhong
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48692687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201408168U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG11201408168UA publication Critical patent/SG11201408168UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau „ (10) International Publication Number (43) International Publication Date ^ ^ WO 2013/188724 A1 19 December 2013 (19.12.2013) WIPO I PCT (51) International Patent Classification: C07D 401/14 (2006.01) A61K 31/497 (2006.01) C07D 403/14 (2006.01) A61P 25/00 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 61/659,911 14 June 2012 (14.06.2012) (74) Agent: LEMOINE, Elsa D.; Amgen Inc., Patent Opera­ tions /MS 28-2-C, One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). PCT/US2013/045768 14 June 2013 (14.06.2013) English (71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). (72) Inventors: ALLEN, Jennifer R.; 139 Via Aldea, Newbury Park, California 91320 (US). CHEN, Jian J.; 5448 Castillo de Rosa, Camarillo, California 93012 (US). FROHN, Michael J.; 2808 Cedar Wood Place, Thousand Oaks, California 91362 (US). KALLER, Matthew Richard; 1644 Red Rock Avenue, Ventura, California 93004 (US). LIU, Qingyian; 4631 Paseo Girasol, Ca­ marillo, California 93012 (US). NGUYEN, Thomas T.; 468 Calle Veracruz, Newbury Park, California 91320 (US). PICKRELL, Alexander J.; 30948 Minute Man Way, Westlake Village, California 91361 (US). QIAN, Weny- uan; 3872 Fountain Street, Camarillo, California 93012 (US). RZASA, Robert M.; 160 Kennedy Avenue, Ven­ tura, California 93003 (US). ZHONG, Wenge; 2921 Venezia Lane, Thousand Oaks, California 91362 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, English MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, us SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) Published: — with international search report (Art. 21(3)) (54) Title: AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS CJ l> 00 00 X (I) i-H (57) Abstract: Azetidine and piperidine compounds of formula (I) as defined in the specification, compositions containing them, O and processes for preparing such compounds and intermediates thereof. Provided herein also are methods of treating cognitive dis - CJ orders or diseases treatable by inhibition of PDE10, such as Huntington's Disease, schizophrenia, bipolar disorder, obsessive-com- Q pulsive disorder, and the like.
SG11201408168UA 2012-06-14 2013-06-14 Azetidine and piperidine compounds useful as pde10 inhibitors SG11201408168UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261659911P 2012-06-14 2012-06-14
PCT/US2013/045768 WO2013188724A1 (en) 2012-06-14 2013-06-14 Azetidine and piperidine compounds useful as pde10 inhibitors

Publications (1)

Publication Number Publication Date
SG11201408168UA true SG11201408168UA (en) 2015-01-29

Family

ID=48692687

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408168UA SG11201408168UA (en) 2012-06-14 2013-06-14 Azetidine and piperidine compounds useful as pde10 inhibitors

Country Status (25)

Country Link
US (3) US8691986B2 (en)
EP (1) EP2864317A1 (en)
JP (1) JP2015519402A (en)
KR (1) KR20150023417A (en)
CN (1) CN104619694A (en)
AP (1) AP2014008136A0 (en)
AR (1) AR091436A1 (en)
AU (1) AU2013274153B2 (en)
BR (1) BR112014031368A2 (en)
CA (1) CA2875802A1 (en)
CL (1) CL2014003391A1 (en)
CO (1) CO7160011A2 (en)
CR (1) CR20150012A (en)
EA (1) EA201590014A1 (en)
HK (1) HK1203935A1 (en)
IL (1) IL235901A0 (en)
MA (1) MA37748B1 (en)
MX (1) MX2014014924A (en)
PE (1) PE20150348A1 (en)
PH (1) PH12014502780A1 (en)
SG (1) SG11201408168UA (en)
TN (1) TN2014000510A1 (en)
TW (1) TWI508959B (en)
UY (1) UY34858A (en)
WO (1) WO2013188724A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG185515A1 (en) 2010-05-13 2012-12-28 Amgen Inc Nitrogen heterocyclic compounds useful as pde10 inhibitors
AR091436A1 (en) * 2012-06-14 2015-02-04 Amgen Inc AZETIDINE AND PIPERIDINE COMPOUNDS USED AS PDE10 INHIBITORS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO2011143129A1 (en) * 2010-05-13 2011-11-17 Amgen Inc. Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
SG185515A1 (en) 2010-05-13 2012-12-28 Amgen Inc Nitrogen heterocyclic compounds useful as pde10 inhibitors
EP2569306A1 (en) * 2010-05-13 2013-03-20 Amgen Inc. Heteroaryloxycarbocyclyl compounds as pde10 inhibitors
JP2013526546A (en) 2010-05-13 2013-06-24 アムジエン・インコーポレーテツド Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors
AR091436A1 (en) * 2012-06-14 2015-02-04 Amgen Inc AZETIDINE AND PIPERIDINE COMPOUNDS USED AS PDE10 INHIBITORS

Also Published As

Publication number Publication date
MA37748B1 (en) 2017-07-31
US9303028B2 (en) 2016-04-05
MA37748A1 (en) 2016-11-30
KR20150023417A (en) 2015-03-05
PE20150348A1 (en) 2015-03-04
EP2864317A1 (en) 2015-04-29
CL2014003391A1 (en) 2015-07-10
US20130338138A1 (en) 2013-12-19
EA201590014A1 (en) 2015-04-30
PH12014502780A1 (en) 2015-02-02
AU2013274153B2 (en) 2016-05-19
TN2014000510A1 (en) 2016-03-30
TWI508959B (en) 2015-11-21
BR112014031368A2 (en) 2017-06-27
US20160176874A1 (en) 2016-06-23
MX2014014924A (en) 2015-03-09
AP2014008136A0 (en) 2014-12-31
IL235901A0 (en) 2015-09-24
AR091436A1 (en) 2015-02-04
US8691986B2 (en) 2014-04-08
HK1203935A1 (en) 2015-11-06
CR20150012A (en) 2015-02-11
US20140148435A1 (en) 2014-05-29
CN104619694A (en) 2015-05-13
US9493459B2 (en) 2016-11-15
JP2015519402A (en) 2015-07-09
CA2875802A1 (en) 2013-12-19
AU2013274153A1 (en) 2014-12-18
UY34858A (en) 2013-11-29
WO2013188724A1 (en) 2013-12-19
CO7160011A2 (en) 2015-01-15
TW201412729A (en) 2014-04-01

Similar Documents

Publication Publication Date Title
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201803726VA (en) Method for applying stable coating on silicone hydrogel contact lenses
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201805838UA (en) Macrocyclic mcl1 inhibitors for treating cancer
SG11201407900WA (en) Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201908012SA (en) Cyclic sulfamide compounds and methods of using same
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201807426WA (en) Immunomodulators
SG11201408186TA (en) Pyridinone and pyridazinone derivatives
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201407427WA (en) Extreme pcr
SG11201807720TA (en) Methods and systems for determining antibiotic susceptibility
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201408261UA (en) Syringe
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201407981RA (en) Compositions comprising an anti-pdgf aptamer and a vegf antagonist
SG11201407372UA (en) Nampt inhibitors
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201406787TA (en) Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies
SG11201900744SA (en) Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
SG11201805001UA (en) Method of treating influenza a
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201908729UA (en) Phenyl derivatives as pge2 receptor modulators